ArticleInternational journal of clinical and experimental pathology2014

Bortezomib-based chemotherapy regimens can improve response in newly diagnosed multiple myeloma patients with bcl-2 and survivin overexpression.

Wen Zeng et al.PubMed ↗Full text ↗

No numbers read from the abstract.